Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

12 Issues per year

IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046



Nitrated apolipoprotein A-I, a potential new cardiovascular marker, is markedly increased in low high-density lipoprotein cholesterol subjects

Ahmed Bakillah1

1GlaxoSmithKline, Research and Development, Clinical Pharmacology and Discovery Medicine, King of Prussia, PA, USA

Corresponding author: Ahmed Bakillah, PhD, DSc, GlaxoSmithKline, R&D, 709 Swedeland Road, King of Prussia, PA 19406, USA Phone: +1-215-828-6481,

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 47, Issue 1, Pages 60–69, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2009.017, December 2008

Publication History

Published Online:


Background: Oxidative stress plays an important role in the pathogenesis of coronary artery disease. Recent work showed that high-density lipoproteins isolated from atherosclerotic lesions and blood of patients with established coronary artery disease contain elevated levels of nitrated apolipoprotein A-I. Methods to quantify nitrated apolipoprotein A-I in the plasma may facilitate in the determination of a correlation between plasma levels of nitrated apolipoprotein A-I and risk of atherosclerosis.

Methods: In this report, the presence of plasma nitrated apolipoprotein A-I in subjects with cardiovascular disease was detected by Western blot analysis and quantified by a newly developed specific sandwich enzyme-linked immunosorbent assay.

Results: The precision of the assay was indicated by the good correlation obtained between enzyme-linked immunosorbent assay and Western blot (r2=0.96). Using these two methods, we were able to detect significant elevations (3-fold increase) of plasma nitrated apolipoprotein A-I in low high-density lipoprotein cholesterol subjects as compared to high-density lipoprotein cholesterol subjects. In addition, we found that both plasma and serum samples can be used by enzyme-linked immunosorbent assay to quantify nitrated apolipoprotein A-I concentrations. More importantly, the degree of nitrated apolipoprotein A-I-containing high-density lipoprotein particles was negatively correlated with levels of circulating apolipoprotein A-I.

Conclusions: Measurement of nitrated apolipoprotein A-I levels by this rapid and reproducible new method has the advantages of great sensitivity with no sample manipulations, thus we suggest that this novel method could be useful to monitor levels of circulating nitrated apolipoprotein A-I in order to investigate its value as a potential biological marker for inflammatory vascular disease.

Clin Chem Lab Med 2009;47:60–9.

Keywords: cardiovascular; enzyme-linked immunosorbent assay (ELISA); high-density lipoprotein; myeloperoxidase; nitrotyrosine

Comments (0)

Please log in or register to comment.